Compare Diageo plc (DEO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Moderna, Inc. — how do they compare? Diageo plc trades at $93.66 (market cap $53.05B), while Moderna, Inc. trades at $64.1 (market cap $24.18B). The key difference: Diageo plc is far larger — about 2.2× Moderna, Inc.'s market cap, and Diageo plc pays a 3.5% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DEO | MRNA | |
|---|---|---|
Market Cap | $53.05B | $24.18B |
Sector | Technology | Health |
52-Week High | $115.33 | $81.80 |
52-Week Low | $72.47 | $22.36 |
Enterprise Value | $72.54B | $20.33B |
Dividend Yield | 3.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.47, down 3.75% on the day, amid mixed earnings and a $1 billion cost-cutting plan announced in August 2026. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentals reveal a P/E of 30.47, net income margin of 8.84%, and recent earnings beats in Q4 2025 and Q2 2026, offset by a Q2 2025 miss. Revenue dipped to $19.6 billion in 2026, with North America weakness pressuring results.
The outlook is cautiously optimistic, driven by cost savings and strategic shifts under CEO Dave Lewis, but risks include regional sales volatility and high debt. Analyst consensus leans buy (48.65%), with price targets suggesting upside, though execution on the turnaround plan is critical for sustained growth.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
